Mammalian Peg Uricase for Therapy of Intractable Gout

Hershfield, Michael S.

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
• Type: Small Business Technology Transfer (STTR) Grants - Phase II (R42)
• Project #: 2R42DK048529-02
• Application #: 2016855
• Study Section: Special Emphasis Panel (ZRG3-SSS-2 (01))
• Project Start: 1994-09-30
• Project End: 1998-08-31
• Budget Start: 1996-09-30
• Budget End: 1997-08-31
• Support Year: 2
• Fiscal Year: 1996

Institution

• Name: Mountain View Pharmaceuticals, Inc.
• City: Menlo Park
• State: CA
• Country: United States
• Zip Code: 94025

Publications

Hershfield, Michael S (2009) Reassessing serum urate targets in the management of refractory gout: can you go too low? Curr Opin Rheumatol 21:138-42

Kelly, S J; Delnomdedieu, M; Oliverio, M I et al. (2001) Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase. J Am Soc Nephrol 12:1001-9